Fontolizumab (Huzaf), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn’s disease

Autor:	T. Pearce, Mária Zakuciová, Gert Van Assche, S. Stoinov, János Lonovics, Davor Štimac, Geert R. D'Haens, Daniel W. Hommes, Boris Vucelić, Tatiana Mikhajlova
Rok vydání:	2004
Předmět:	Moderate to severe Crohn's disease Hepatology biology business.industry Gastroenterology medicine.disease Tolerability Immunology medicine biology.protein Fontolizumab Antibody business Ifn gamma medicine.drug
Zdroj:	Gastroenterology. 127:332
ISSN:	0016-5085
DOI:	10.1053/j.gastro.2004.05.011
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b7d8c01f9e5ae3097680eeb5702e4baf https://doi.org/10.1053/j.gastro.2004.05.011 Zobrazit plný text záznamu